PE20121394A1 - Formulacion que comprende derivados 1h-quinazolina-2,4-diona como antagonistas de receptores ampa, en forma de tabletas de liberacion inmediata y preparaciones de la misma - Google Patents

Formulacion que comprende derivados 1h-quinazolina-2,4-diona como antagonistas de receptores ampa, en forma de tabletas de liberacion inmediata y preparaciones de la misma

Info

Publication number
PE20121394A1
PE20121394A1 PE2012000861A PE2012000861A PE20121394A1 PE 20121394 A1 PE20121394 A1 PE 20121394A1 PE 2012000861 A PE2012000861 A PE 2012000861A PE 2012000861 A PE2012000861 A PE 2012000861A PE 20121394 A1 PE20121394 A1 PE 20121394A1
Authority
PE
Peru
Prior art keywords
tablet
quinazoline
weight
amount
antagonists
Prior art date
Application number
PE2012000861A
Other languages
English (en)
Inventor
Joseph Lawrence Zielinski
John Vrettos
Qin Ji
Subash Patel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43610748&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20121394(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20121394A1 publication Critical patent/PE20121394A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Addiction (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

REFERIDA A UNA FORMULACION FARMACEUTICA BAJO LA FORMA DE TABLETA QUE COMPRENDE: HIDROXIPROPILCELULOSA EN UNA CANTIDAD DE ENTRE 2% Y 10% POR PESO DE LA TABLETA Y UN COMPUESTO ACTIVO DERIVADO DE 1H-QUINAZOLINA-2,4-DIONA DE FORMULA (I) EN UNA CANTIDAD DE ENTRE 5% Y 27,5% POR PESO DE LA TABLETA, DONDE R1 ES CF3, CHF2, CH2F, CH3CHF, ENTRE OTROS; R2 ES ALQUILO SUSTITUIDO POR HALOGENO, NITRO, CIANO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS DE FORMULA (I): (i), (ii), (iii), ENTRE OTROS. TAMBIEN PUEDE COMPRENDER UN RELLENO INSOLUBLE EN AGUA TAL COMO CELULOSA MICROCRISTALINA, EN UNA CANTIDAD DE 25% A 50% POR PESO DE LA TABLETA, UN DESINTEGRADOR TAL COMO GLICOLATO SODICO DE ALMIDON EN UNA CANTIDAD DE 2,5% A 15% POR PESO DE LA TABLETA, Y OTROS EXCIPIENTES TALES COMO UN AYUDANTE DE FLUJO Y UN LUBRICANTE. TAMBIEN ESTA REFERIDA A UN PROCESO DE PREPARACION. DICHOS COMPUESTOS DE FORMULA (I) TIENEN ACTIVIDAD ANTAGONISTA DEL RECEPTOR AMPA
PE2012000861A 2009-12-22 2010-12-21 Formulacion que comprende derivados 1h-quinazolina-2,4-diona como antagonistas de receptores ampa, en forma de tabletas de liberacion inmediata y preparaciones de la misma PE20121394A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28898509P 2009-12-22 2009-12-22

Publications (1)

Publication Number Publication Date
PE20121394A1 true PE20121394A1 (es) 2012-10-29

Family

ID=43610748

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000861A PE20121394A1 (es) 2009-12-22 2010-12-21 Formulacion que comprende derivados 1h-quinazolina-2,4-diona como antagonistas de receptores ampa, en forma de tabletas de liberacion inmediata y preparaciones de la misma

Country Status (19)

Country Link
US (1) US20120263791A1 (es)
EP (1) EP2515873A1 (es)
JP (1) JP2013515076A (es)
KR (1) KR20120105035A (es)
CN (2) CN104013587A (es)
AU (1) AU2010336510B2 (es)
BR (1) BR112012016920A2 (es)
CA (1) CA2784996A1 (es)
CL (1) CL2012001689A1 (es)
EC (1) ECSP12011994A (es)
GT (1) GT201200209A (es)
MA (1) MA33834B1 (es)
MX (1) MX2012007320A (es)
NZ (1) NZ600717A (es)
PE (1) PE20121394A1 (es)
RU (1) RU2012131051A (es)
SG (1) SG181787A1 (es)
WO (1) WO2011079119A1 (es)
ZA (1) ZA201204607B (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2465693A1 (en) * 2003-06-12 2004-12-12 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
GB0416730D0 (en) * 2004-07-27 2004-09-01 Novartis Ag Organic compounds
GB0507298D0 (en) * 2005-04-11 2005-05-18 Novartis Ag Organic compounds
KR20080002939A (ko) * 2005-04-12 2008-01-04 엘란 파마 인터내셔널 리미티드 나노입자형 퀴나졸린 유도체 제제
JOP20180109A1 (ar) * 2005-09-29 2019-01-30 Novartis Ag تركيبة جديدة
EP1968553A2 (en) * 2005-11-09 2008-09-17 Novartis AG Process for making pharmaceutical compositions with a transient plasticizer
EP2251012A4 (en) * 2008-02-11 2013-03-06 Dainippon Sumitomo Pharma Co TABLET HAVING ENHANCED ELUTING PROPERTIES

Also Published As

Publication number Publication date
CA2784996A1 (en) 2011-06-30
WO2011079119A1 (en) 2011-06-30
ZA201204607B (en) 2013-02-27
MX2012007320A (es) 2012-07-20
JP2013515076A (ja) 2013-05-02
EP2515873A1 (en) 2012-10-31
NZ600717A (en) 2014-06-27
KR20120105035A (ko) 2012-09-24
US20120263791A1 (en) 2012-10-18
AU2010336510B2 (en) 2014-06-26
CN104013587A (zh) 2014-09-03
MA33834B1 (fr) 2012-12-03
RU2012131051A (ru) 2014-01-27
AU2010336510A1 (en) 2012-07-12
ECSP12011994A (es) 2012-07-31
BR112012016920A2 (pt) 2016-04-12
CL2012001689A1 (es) 2013-01-11
CN102770124A (zh) 2012-11-07
GT201200209A (es) 2013-09-09
SG181787A1 (en) 2012-07-30

Similar Documents

Publication Publication Date Title
CY1116328T1 (el) Παραγωγα 4 - αμινοπυριμιδινης και η χρηση τους ως ανταγωνιστων α2α υποδοχεων αδενοσινης
EA201391662A1 (ru) Соединения с активностью антагонистов мускариновых рецепторов и агонистов адренергического рецептора бета2
PH12015501247B1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
UA99132C2 (ru) Производные дикарбоновых кислот как агонисты рецепторов s1p1
MX2012010966A (es) Derivados de triazina disustituidos farmaceuticamente activos.
UA110310C2 (uk) Сполуки n-арилтриазолу як антагоністи рецепторів лізофосфатидної кислоти (lpar)
JO3078B1 (ar) مورفولينوثيازولات بصفتها منظمات الوستيرية نوع الفا 7 موجبة
PH12017501424B1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
MX2023001812A (es) Compuestos del acido azociclohexil acetico sustituidos por triazol-piridinilo como antagonistas del receptor lpa.
PE20121131A1 (es) Composicion farmaceutica oral solida en comprimido monocapa que comprende irbesartan y besilato de amlodipina
CR20150322A (es) Nuevos derivados carbamato de ciclohexilo y quinuclidinilo que tienen actividad como agonistas b2 adrenérgicos y como antagonistas muscarínicos m3
AU2014374259A1 (en) Novel compositions
NZ599762A (en) Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
KR20100020459A (ko) 지연 방출형 제제 및 아드레날린 조절부전의 치료방법
PE20091900A1 (es) Una formulacion farmaceutica solida
PE20121394A1 (es) Formulacion que comprende derivados 1h-quinazolina-2,4-diona como antagonistas de receptores ampa, en forma de tabletas de liberacion inmediata y preparaciones de la misma
ES2847904T3 (es) Medicamento para la prevención o el tratamiento de la hipertensión
MX2017015047A (es) Compuestos que tienen actividad antagonista del receptor muscarinico y actividad agonista del receptor beta2 adrenergico.
MX2009012933A (es) Derivados de ariloxazol ariloxadiazol y bencimidazol como moduladores de la actividad del receptor de somatostatinas.
RU2011145436A (ru) Композиции с немедленным высвобождением лекарственного средства
JP6018420B2 (ja) アンジオテンシンｉｉ受容体拮抗薬およびサイアザイド系利尿薬を含む医薬組成物
TR201206999T1 (tr) Telmisartan ve hidroklorotiazid içeren farmasotik kompozisyonlar.
MX350516B (es) Compuestos de anillo fusionado que contienen nitrogeno como antagonistas crth2.
PE20121404A1 (es) Formulacion de liberacion controlada de carvedilol
AR072477A1 (es) Formulacion farmaceutica de eprosartan. uso.

Legal Events

Date Code Title Description
FD Application declared void or lapsed